Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.79 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.73 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.73 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.73 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10327748 | 0.92 | PIK3CA (0.72) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL1821372 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL14748416 | 0.88 | PIK3CA (0.81) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1820789 | 0.86 | PIK3CA (0.82) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1821363 | 0.86 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1819312 | 0.86 | PIK3CA (0.81) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1820153 | 0.86 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL10327924 | 0.84 | PIK3CA (0.65) | PIK3CAPIK3CGPIK3CDPIK3CBMTOR | |
| SCHEMBL1821854 | 0.84 | PIK3CA (1.00) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1823772 | 0.84 | PIK3CA (0.81) | PIK3CAPIK3CGPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | PIK3CA 1/4885PIK3CG 22/4885PIK3CD 16/4885 |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | PIK3CA 1/4885PIK3CG 20/4885PIK3CD 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.